Consistent with this, broader literature links TICRR overexpression to adverse outcomes in other cancers (e.g., endometrial and papillary renal cell carcinoma) and to cell-cycle/replication control, underscoring the generalizability of our findings (19, 20). This evidence concerns the gene TICRR and cancer.